Hospira
LONDON, October 12, 2010 - Raltitrexed (Tomudex(R)) in combination with cisplatin in the treatment
of MPM improves median overall survival compared to treatment with cisplatin
alone.[1] With incidence rates expected to double over the next 20 years in
many countries[2], new and effective treatments are a welcome addition,
concluded an eminent panel of international speakers at a symposium sponsored
by Hospira at the 35th congress of the European Society for Medical Oncology
(ESMO), Milan.
LEAMINGTON SPA, England, October 4, 2010 - Hospira (NYSE: HSP), a global specialty pharmaceutical and medication
delivery company, announced today that Svend Andersen has been named
corporate vice president and president, Europe, Middle East and Africa
(EMEA).
LONDON, February 22, 2010 - Hospira announced today that the European Committee for Medicinal
Products for Human Use (CHMP) has recommended for approval the administration
of Retacrit (epoetin zeta) subcutaneously in the nephrology setting.
LEAMINGTON SPA, England -
-- Single-Vial Formulation Designed to Improve Safety --
Hospira, Inc.
LAKE FOREST, Illinois -
-- Expands Biologics Manufacturing/Commercial Capabilities --
Hospira, Inc.
